MariMed Inc. (OTCMKTS:MRMD) Short Interest Update

MariMed Inc. (OTCMKTS:MRMD) was the recipient of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 1,025 shares, a decrease of 81.7% from the December 31st total of 5,595 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 945,496 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 945,496 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

MariMed Stock Up 0.2%

MRMD stock opened at $0.09 on Thursday. The firm has a market cap of $34.50 million, a PE ratio of -2.18 and a beta of 1.04. The company has a debt-to-equity ratio of 1.34, a quick ratio of 0.35 and a current ratio of 1.06. The firm’s fifty day moving average is $0.09 and its 200 day moving average is $0.12. MariMed has a one year low of $0.07 and a one year high of $0.23.

MariMed (OTCMKTS:MRMD) last posted its earnings results on Wednesday, November 5th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.01). MariMed had a negative net margin of 11.36% and a negative return on equity of 14.67%. The business had revenue of $40.76 million for the quarter, compared to analyst estimates of $42.15 million.

Analyst Ratings Changes

Several analysts have commented on MRMD shares. Ventum Cap Mkts cut shares of MariMed from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 7th. Zacks Research raised shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.